The Pathophysiologic Role of Incretins

No abstract is available for this paper.

• Publication year

  2007

• Venue

  The Journal of the American Osteopathic Association

• Publication date

  2007-05-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.7556/jaoa.2007.20006PMID 17724014
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Reduced incretin effect in Type 2 (non-insulin-dependent) diabetes

  2006cited by this paper
• Incretin-Based Therapies

  2006cited by this paper
• Inhibition of dipeptidyl peptidase-4 augments insulin secretion in response to exogenously administered glucagon-like peptide-1, glucose-dependent insulinotropic polypeptide, pituitary adenylate cyclase-activating polypeptide, and gastrin-releasing peptide in mice.

  2005cited by this paper
• Inhibition of dipeptidyl-peptidase IV catalyzed peptide truncation by Vildagliptin ((2S)-{[(3-hydroxyadamantan-1-yl)amino]acetyl}-pyrrolidine-2-carbonitrile).

  2005cited by this paper
• Glucagon- Like Peptide-1-Based Therapies for the Treatment of Type 2 Diabetes Mellitus

  2005cited by this paper
• Poor control of risk factors for vascular disease among adults with previously diagnosed diabetes.

  2004cited by this paper
• Incretins, insulin secretion and Type 2 diabetes mellitus

  2004cited by this paper
• Poor control of risk factors for vascular disease among adults with previously diagnosed diabetes

  2004cited by this paper
• Clinical endocrinology and metabolism. Glucose-dependent insulinotropic polypeptide/gastric inhibitory polypeptide.

  2004cited by this paper
• Glucose-dependent insulinotropic polypeptide/gastric inhibitory polypeptide

  2004cited by this paper
• Glycemic control from 1988 to 2000 among U.S. adults diagnosed with type 2 diabetes: a preliminary report.

  2004cited by this paper
• Enhancing incretin action for the treatment of type 2 diabetes.

  2003cited by this paper
• Glucagon-like peptide-1 and the islet beta-cell: augmentation of cell proliferation and inhibition of apoptosis.

  2003cited by this paper
• Economic costs of diabetes in the US in 2002.

  2003cited by this paper
• Determinants of the impaired secretion of glucagon-like peptide-1 in type 2 diabetic patients.

  2001cited by this paper
• Dipeptidyl-peptidase IV (CD26)--role in the inactivation of regulatory peptides.

  1999cited by this paper
• The natural history of insulin secretory dysfunction and insulin resistance in the pathogenesis of type 2 diabetes mellitus.

  1999cited by this paper
• Secretion of the incretin hormones glucagon-like peptide-1 and gastric inhibitory polypeptide correlates with insulin secretion in normal man throughout the day.

  1996cited by this paper
• Cell and molecular biology of the incretin hormones glucagon-like peptide-I and glucose-dependent insulin releasing polypeptide.

  1995cited by this paper
• Degradation of glucagon-like peptide-1 by human plasma in vitro yields an N-terminally truncated peptide that is a major endogenous metabolite in vivo.

  1995cited by this paper
• Incretin effects of increasing glucose loads in man calculated from venous insulin and C-peptide responses.

  1986cited by this paper
• Abnormal alpha-cell function in diabetes. Response to carbohydrate and protein ingestion.

  1970cited by this paper
• rapid communication Glucagon-like peptide-1 promotes satiety and reduces food intake in patients with diabetes mellitus type 2

  year unknowncited by this paper

• The role of incretin-based therapies in the management of type 2 diabetes mellitus: perspectives on the past, present and future

  2020cites this paper
• DPP-4 inhibitor improves learning and memory deficits and AD-like neurodegeneration by modulating the GLP-1 signaling.

  2019cites this paper
• The Effect of Acute Aerobic Exercise on Glucagon -like peptide-1 (GLP-1) Serum Changes Levels, in Women with Type 2 Diabetes Mellitus

  2017cites this paper
• Controle Neuroendócrino da Saciedade

  2016cites this paper
• Combination of Sitagliptin and Insulin against Type 2 Diabetes Mellitus with Neuropathy in Rats: Neuroprotection and Role of Oxidative and Inflammation Stress

  2016cites this paper
• Asymmetric dimethylarginine, a biomarker of cardiovascular complications in diabetes mellitus.

  2015cites this paper
• What’s next after metformin? focus on sulphonylurea: add-on or combination therapy

  2015cites this paper
• The Effect of Glucagon-Like Peptide 1 Receptor Agonists on Weight Loss in Type 2 Diabetes: A Systematic Review and Mixed Treatment Comparison Meta-Analysis

  2015cites this paper
• Profile of saxagliptin in the treatment of type 2 diabetes: focus on Japanese patients

  2014cites this paper
• Profile of saxagliptin in the treatment of type 2 diabetes: focus on Japanese patients

  2014cites this paper
• Incretin Hormones and their effects in Type 2 Diabetes

  2014cites this paper
• The Effect of High Fat Diet and High Fructose Intake on Insulin Resistance and GLP-1 in Experimental Animals

  2013cites this paper
• Profile of vildagliptin in type 2 diabetes: efficacy, safety, and patient acceptability

  2013cites this paper
• Global Cardiovascular Risk Reduction in People with Diabetes Mellitus and Hypertension

  2012cites this paper
• Linagliptin, a dipeptidyl peptidase-4 inhibitor with a unique pharmacological profile, and efficacy in a broad range of patients with type 2 diabetes

  2012cites this paper
• Dipeptidyl Peptidase IV Inhibitor Attenuates Kidney Injury in Streptozotocin-Induced Diabetic Rats

  2012cites this paper
• Impact of Physical Activity on Postprandial Lipidemia and Glycemic Control after Chronic Fructose Ingestion

  2012cites this paper
• Dipeptidyl Peptidase (DPP) IV Inhibitor Attenuates Kidney Injury in Streptozotocin Induced Diabetic Rats

  2011cites this paper
• Managing Hyperglycemia in Patients With Type 2 Diabetes Mellitus: Rationale for the Use of Dipeptidyl Peptidase-4 Inhibitors in Combination With Other Oral Antidiabetic Drugs

  2010cites this paper
• Type 2 Diabetes Mellitus: Epidemiology, Genetics, Pathogenesis, and Clinical Manifestations

  2010cites this paper
• Incretinas: opción terapéutica para la diabetes mellitus tipo 2

  2010cites this paper
• A physiologic and pharmacological basis for implementation of incretin hormones in the treatment of type 2 diabetes mellitus.

  2010cites this paper
• Procédés et compositions destinés à la modulation de la régulation de l’insuline

  2009cites this paper
• Role of the incretin pathway in the pathogenesis of type 2 diabetes mellitus

  2009cites this paper
• Making Sense of Digestive Enzymes

  2008cites this paper